Results 111 to 120 of about 36,083 (204)

Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes. [PDF]

J Diabetes Res
Jimoh AO, Hudu SA, Sabir AA, Adamu AA, Bello N, Tahir A, Abubakar N.   +6 more
europepmc   +1 more source

NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach. [PDF]

Front Bioinform
Hossain D, Saghapour E, Chen JY.
europepmc   +1 more source

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents. [PDF]

Molecules, 2023
Mathur V, Alam O, Siddiqui N, Jha M, Manaithiya A, Bawa S, Sharma N, Alshehri S, Alam P, Shakeel F.   +9 more
europepmc   +1 more source

Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors. [PDF]

Int J Mol Sci
Król M, Kupnicka P, Żychowska J, Kapczuk P, Szućko-Kociuba I, Prajwos E, Chlubek D.   +6 more
europepmc   +1 more source

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review. [PDF]

Adv Ther
Pantazopoulos D, Gouveri E, Papi M, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes. [PDF]

Future Virol, 2023
Nag S, Mandal S, Mukherjee O, Mukherjee S, Kundu R.   +4 more
europepmc   +1 more source

Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention/treatment of the disruption of cardio-cerebrovascular homeostasis. [PDF]

Front Pharmacol
Pavlović KT, Anderluh M, Šmelcerović A.   +2 more
europepmc   +1 more source

Beyond glycemic control: the cardiac and hepatic benefits of SGLT2 and DPP-4 inhibitors in mitigating chronic cadmium-induced inflammation, oxidative/nitrative stress, apoptosis and fibrosis. [PDF]

Front Physiol
Hassan FE, Hassanien MM, Selmy A, Mahmoud LM, Darwish A, Aldreny BA.   +5 more
europepmc   +1 more source

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. [PDF]

Diabetol Metab Syndr
Hajishah H, Mazloom P, Salehi A, Kazemi D, Samiee R, Majlesi H, Amini MJ, Meyari A, Dehnavi NS, Zangi M.   +9 more
europepmc   +1 more source